Other Posts
Abstract #LBA47: Masahiro Tsuboi presented two-year follow-up data of disease free survival (DFS) and recurrence patterns from the P3 ADAURA trial, which compared osimertinib(n=339) versus placebo (n=343) in patients with completely resectedEGFRm stage IBꟷIIIA NSCLC ± adjuvant CT.
Results: ContinuedDFS benefit was sustained with osimertinib vs placebo, consistent with the primary analysis. Median DFS was 65.8 mos vs 21.9 mos in osimertinib vs placebo arms, respectively. Fewer pts experienced local/regional and distant recurrence in osimertinib arm vsplacebo (27% vs 60%). Long-term safety profile consistent with known profile of osimertinib.
Oncologist thought leaders cite that DFS remains very impressive for Osimertinib in early EGFRm NSCLC; however, several wonder whether the treatment is more preventative vs. curative
Several commentators are somewhat disappointed to not yet see overall survival (OS) data
A few oncologists mention a particular benefit in reducing CNS relapse
Two-year follow-up data from the ADAURA shows impressive disease-free survival benefit with osimertinib in completely resected EGFRm stage IBꟷIIIA NSCLC, particularly with respect to CNS. Based on KM curves, numerous commentators suspect the treatment may have a more preventative vs. curative effect; they seek OS data to clarify this question.
Synthesis by Opus Strategy, LLC.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
